HUYA Bioscience And Quintiles Announce Partnership For Phase I Development Of New Cancer Therapy

China-sourced cancer drug enters U.S. clinical trials

San Diego, CA & Research Triangle Park, N.C. – September 28, 2010 — HUYA Bioscience International (HUYA), the leader in U.S.-China pharmaceutical co-development, and Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced an agreement to co- develop a new cancer drug, HBI-8000, sourced in China by HUYA. Read more

HUYA Biosciences Establishes Strategic Partnership With Sun Yat-Sen University’s School Of Pharmaceutical Sciences

San Diego, CA, USA – August 30, 2010 — HUYA Bioscience International, a company at the forefront of globalizing China’s biopharmaceutical innovations, today announced a strategic partnership with the School of Pharmaceutical Sciences at Sun Yat-sen University (SYSU). The collaborative agreement expands HUYA’s foothold in Southern China, aiming to accelerate the development of novel drugs arising from the school’s research efforts. Read more

HUYA Bioscience International And China Medical City Forge Alliance To Help Develop China’s Pharmaceutical Industry

San Diego, CA, USA – June 28, 2010 — HUYA Bioscience International, a leader in globalizing China’s pharmaceutical innovations, today announced a strategic partnership with the Taizhou National Medical Hi-tech Development Zone, also known as “China Medical City” (CMC). The alliance will combine both parties’ strengths in pharmaceutical product R&D and commercialization in order to promote China’s pharmaceutical-biotech industry to the world- class level. Read more

HUYA Bioscience International Strengthens R&D Leadership In Traditional Chinese Medicine With The School Of Chinese Materia Medica, Beijing University Of Chinese Medicine

San Diego, CA, USA – May 28, 2010 — HUYA Bioscience International, a leader in globalizing China’s biopharmaceutical innovation, today announced a strategic partnership with the School of Chinese Materia Medica of the Beijing University of Chinese Medicine (BUCM). As one of a series of collaborations that HUYA has established with China’s leading research and development institutions, the agreement demonstrates HUYA’s visionary commitment to enabling and accelerating the global development and commercialization of novel biopharmaceutical products originating in China. Read more